Intraocular medulloepithelioma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:268139D31.4
Who is this for?
Show terms as
16Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Intraocular medulloepithelioma, also known as diktyoma, is a rare embryonal neoplasm arising from the nonpigmented ciliary epithelium of the eye. This tumor originates from the medullary epithelium, which is the primitive neuroepithelial tissue that normally gives rise to structures of the eye during embryonic development. It is the most common tumor of the ciliary body in children and is typically diagnosed in early childhood, usually before the age of 10 years. Intraocular medulloepithelioma can be classified as benign (nonteratoid or teratoid) or malignant (nonteratoid or teratoid). Teratoid variants contain heteroplastic elements such as cartilage, brain tissue, or skeletal muscle. Key clinical features include a visible mass in the ciliary body region, decreased vision, leukocoria (white pupillary reflex), pain, glaucoma, lens subluxation or cataract, and neovascularization of the iris. The tumor may also present with a characteristic cyst or multiple cysts within the anterior segment of the eye. In some cases, the tumor can be associated with persistent hyperplastic primary vitreous or other developmental ocular anomalies. Rarely, intraocular medulloepithelioma has been reported in association with pleuropulmonary blastoma familial tumor and dysplasia syndrome linked to DICER1 mutations. Treatment depends on the size and extent of the tumor. Small, localized tumors may be managed with local resection (iridocyclectomy or partial lamellar sclerouvectomy), plaque brachytherapy, or cryotherapy. However, enucleation (surgical removal of the eye) remains the most common treatment, particularly for larger tumors or those with secondary complications such as glaucoma or extensive intraocular involvement. Malignant variants carry a risk of local invasion and, rarely, distant metastasis. Early diagnosis and treatment are critical to preserving vision when possible and preventing extraocular spread. Prognosis is generally favorable when the tumor is confined to the eye, but outcomes worsen significantly with extraocular extension.

Also known as:

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Intraocular medulloepithelioma.

View clinical trials →

No actively recruiting trials found for Intraocular medulloepithelioma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Intraocular medulloepithelioma community →

Specialists

16 foundView all specialists →
SM
Sukriti Mohan
CHICAGO, IL
Specialist
1 Intraocular medulloepithelioma publication
MS
Maria Elena Sibug Saber
Specialist
1 Intraocular medulloepithelioma publication
XY
Xiuqian Yi
Specialist
1 Intraocular medulloepithelioma publication
FM
Fengxi Meng
Specialist
1 Intraocular medulloepithelioma publication
YB
Yingwen Bi
Specialist
1 Intraocular medulloepithelioma publication
LH
Lin He
Specialist
1 Intraocular medulloepithelioma publication
KX
Kang Xue
Specialist
1 Intraocular medulloepithelioma publication
UI
Uzma Imam
Specialist
1 Intraocular medulloepithelioma publication
MH
Marya Hameed
Specialist
1 Intraocular medulloepithelioma publication
IA
Irma Anis
Specialist
1 Intraocular medulloepithelioma publication
IB
Israr Bhutto
Specialist
1 Intraocular medulloepithelioma publication
SA
Syed Habib Ahmed
Specialist
1 Intraocular medulloepithelioma publication
WG
William Steven Gange
FORT COLLINS, CO
Specialist
1 Intraocular medulloepithelioma publication
AR
Attiya Rizvi
Specialist
1 Intraocular medulloepithelioma publication
JQ
Jiang Qian
ALBANY, NY
Specialist
1 Intraocular medulloepithelioma publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Intraocular medulloepithelioma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Intraocular medulloepitheliomaForum →

No community posts yet. Be the first to share your experience with Intraocular medulloepithelioma.

Start the conversation →

Latest news about Intraocular medulloepithelioma

No recent news articles for Intraocular medulloepithelioma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Intraocular medulloepithelioma

What is Intraocular medulloepithelioma?

Intraocular medulloepithelioma, also known as diktyoma, is a rare embryonal neoplasm arising from the nonpigmented ciliary epithelium of the eye. This tumor originates from the medullary epithelium, which is the primitive neuroepithelial tissue that normally gives rise to structures of the eye during embryonic development. It is the most common tumor of the ciliary body in children and is typically diagnosed in early childhood, usually before the age of 10 years. Intraocular medulloepithelioma can be classified as benign (nonteratoid or teratoid) or malignant (nonteratoid or teratoid). Terato

How is Intraocular medulloepithelioma inherited?

Intraocular medulloepithelioma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Intraocular medulloepithelioma typically begin?

Typical onset of Intraocular medulloepithelioma is childhood. Age of onset can vary across affected individuals.

Which specialists treat Intraocular medulloepithelioma?

16 specialists and care centers treating Intraocular medulloepithelioma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.